Prazosin kinetics in essential hypertension.
Prazosin kinetics were studied in 8 hypertensive patients (4 male and 4 female) with normal renal function. Intravenous data showed a 3-phase distribution. As a result, a linear 3-compartment model with elimination from the central compartment was proposed to describe the drug kinetics. Prazosin disappeared from plasma with a terminal half-life t1/2 of about 3 hr and had a central distribution volume of about 0.18 1/kg. Only a negligible fraction of the dose was found unchanged in urine. The oral data showed that, of the 2-mg dose, about 1 mg was effectively absorbed. This fraction was almost entirely absorbed in 2 hr. Absorption kinetics were apparently linear with a t1/2 of about 30 min.
D000042:Absorption; D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D005260:Female; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism*; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011224:Prazosin / Q000008:administration & dosage / Q000378:metabolism*; D011799:Quinazolines / Q000378:metabolism*
D011799:Quinazolines; D011224:Prazosin